Social Security faces a projected 22% benefit cut by 2032, requiring a 30%+ increase in personal retirement contributions for average Americans. I advocate a diversified, income-focused portfolio with high-quality dividend payers like Antero Midstream, MPLX LP, CME Group, and Union Pacific to balance yield, growth, and liquidity. Sequence of return risk is a critical threat near retirement; laddering short-term Treasuries and relying on dividend income can mitigate forced equity sales.
@OptionsPlay's Tony Zhang offers his takeaways on the broad tech strength in Thursday's trading session as Nvidia (NVDA) gives new life to the sector. He outlines options trading opportunities in CME Group (CME) and Marvell (MRVL) and makes a bull case in both even if the stock market is hit with another volatility wave.
CME Group remains a Buy, driven by robust volumes, an expanding fixed-income ecosystem, and product innovation, despite a full valuation. CME's Q2 2026 saw record revenues, strong margins near 70%, and notable growth in international and retail trading volumes. Key catalysts include Treasury Link integration, 24/7 trading, Compute futures, and regulatory tailwinds in clearing requirements.
CME (CME) reported earnings 30 days ago. What's next for the stock?
CME Group operates as the world's leading derivatives marketplace, serving as essential infrastructure for stock and fixed income markets. CME benefits from interest rate volatility, proprietary benchmark products, and a high-margin, recurring revenue model with 33 consecutive quarters of market data growth. Shares trade at a forward P/E of 21.8, a 9% discount to a $290 fair value estimate; consensus expects 7.5% annual EPS growth through 2028.
CME Group leads Coinbase on valuation, price gains and near-term growth, even as both expand across crypto and global trading markets.
Geopolitical uncertainty isn't taking weekends off, and neither are investors, as they embrace CME Group's 24/7 one-ounce gold contract.
CME Group has underperformed the S&P 500, declining nearly 12% over the past 11 months. CME delivered solid Q2 2026 results, with EPS of $2.99 and revenue of $1.71B, both of which beat analysts' expectations. Market Data revenue surged more than 20% compared to the same period a year ago.
CME Group is rated Buy, supported by record results and a resilient, defensible futures franchise. CME's moat is anchored in open interest and margin efficiencies, not just market share, insulating it from FMX's cash bond competition. Three underappreciated growth drivers: Treasury clearing, retail expansion, and crypto, are poised to fuel future compounding.
CME Group maintains strong core performance, posting record Q2 revenue and robust margins, yet the stock remains range-bound and fully valued. Q2 2026 highlights include $2.99 non-GAAP EPS, $1.71B revenue, 69.5% adjusted operating margin, and resilient trading volumes across key product lines. Capital return remains aggressive with $1.2B distributed via dividends and buybacks, backed by a strong balance sheet and disciplined expense management.
CME Group Inc. (CME) Q2 2026 Earnings Call Transcript
CME Group beats Q2 estimates as record market data revenues and resilient trading activity lift results, while expanding its product lineup.